Nephron’s $215M vaccine expansion

Special To The Chronicle
Posted 11/26/20

Nephron Pharmaceuticals CEO Lou Kennedy has reason for optimism.

Last week’s beam-raising ceremony marked a milestone for the $215.8 million expansion at Nephron Pharmaceutical Corp.’s …

This item is available in full to subscribers.

Subscribe to continue reading. Already a subscriber? Sign in

Get 50% of all subscriptions for a limited time. Subscribe today.

You can cancel anytime.
 

Please log in to continue

Log in

Nephron’s $215M vaccine expansion

Posted

Nephron Pharmaceuticals CEO Lou Kennedy has reason for optimism.

Last week’s beam-raising ceremony marked a milestone for the $215.8 million expansion at Nephron Pharmaceutical Corp.’s Lexington County campus.

The expansion is expected to create 380 jobs and includes a 110,000-square-foot vaccine production, chemotherapy and antibiotic wing.

Kennedy says she expects it to be up and running by next March.

Nephron seeks a vaccine production partner for the pre-filled sterile syringes that make up its 503B Outsourcing.

Possibilities include 2 covid vaccine makers, Moderna and Pfizer, which are near release of their drugs.

Moderna said preliminary data found its vaccine 94.5% effective.

Pfizer announced a 90% effectiveness rate for its vaccine.

Nephron has received FDA approval to run all 12 of its production lines in response to increased demand for its inhalation solutions during the pandemic.

“Our products are not approved for the treatment of covid-19 or its symptoms,” Kennedy said.

“We have worked with the FDA to develop and obtain approval of additional prescription product lines, began manufacturing hand sanitizer, and recently opened a CLIA-certified diagnostics lab.”

The expansion will allow Nephron to make more ingredients it needs as supply chain disruptions have slowed production.

Comments

No comments on this item Please log in to comment by clicking here